(26 Apr 2022) “Dr. Anan” Chongkaewwatana, a researcher in virology, Biotech, posted a message on Facebook. Anan Jongkaewwattana stated that before, we would have heard the exciting news of “Covid drug” Antibody type called “Sotrovimab” The preliminary results in the laboratory found that It may be effective once morest all strains of COVID-19, including mutant viruses such as “Omicron” or “Omicron” It is also hoped that COVID patients at risk of severe symptoms especially from escaped species such as BA.1 or BA.2
“Dr. Anan” said, but the latest information revealed seems to be bad news Results of a study in patients with BA.2 covid-19 in Qatar using “Sotrovimab” In the treatment, the antibodies in the aforementioned formulations were found to There was no effect in reducing the severe symptoms of COVID-19 patients infected with Omicron BA.2 virus. Patients using this antibody formulation There was a chance that patients were more likely to get sick than those who did not use the drug.
The results of this study appear to contradict previous studies that tested patients not infected with BA.2, leading the team to believe that BA.2 may have escaped antibody binding in this formulation better than previous strains. this This is consistent with FDA recommendations not to use this formulation of antibody in areas where BA.2 is a major strain.
for “Sotrovimab” or trade name Xevudy, previously identified as “Covid drug” with antibodies All species, including “Omicron” also developed through cooperation between companies GlaxoSmithKline (GSK), Britain’s pharmaceutical giant and Vir Biotechnology from the US, have released preliminary results from the study. The drug is effective once morest all strains of COVID-19, including mutant viruses like “Omicron” It has mutations in as many as 37 spike protein sites and has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA).
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved it. “Sotrovimab” under the trade name Xevudy for use in patients with COVID-19 mild to moderate and those who are at high risk of developing serious illnesses The goal is to stop the incidence of severe illnesses among those who have been infected with COVID-19. and useful For people with weakened immune systems, the MHRA recommends taking the drug as soon as possible or within 5 days of onset of illness.
